BioSpace News Archive

R-Zero, a biosafety company dedicated to developing the most effective hospital-grade technologies to reduce the spread of infectious disease, today announced $15M in new capital and remarkable business momentum, just three months after first introducing its germicidal UV device.

Amedisys, Inc., one of America’s leading home health, hospice and personal care companies, announced that Paul B. Kusserow, President and Chief Executive Officer will present at the Stephens Annual Investment Conference 2020 on Thursday, November 19, 2020.

American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T , a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing and required safety testing, the product will be infused back into the tr

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights: Generated total revenue of $10.8 million for the quarter ended September 30, 2020, an increase of 20% over the quarter ended June 30, 2020 and 3% over the quarter ended September 30, 2019. Delivered 26,201

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29 th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representative

Third quarter GAAP net sales of $1.13 billion, an increase of 11% year-over-year; non-GAAP organic net sales increased 12% year-over-year

– Updated clinical data from BIO89-100 ’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planni ng to initiate the Phase 2b trial as part of the Phase 2b/3 program in NASH in 1H21 – – Topline results from BIO89-100’s Phase 2 SHTG trial expected in 2H21

Curis, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, a component of the National Institutes of Health, for joint development of CA-4948, a first-in-class small molecule IRAK4 kinase inhibitor, as an anti-cancer agent under the NCI Experimental Therapeutics Program.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter ended September 30, 2020 and highlighted recent corporate progress.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million . The company also recorded an additional $750,000 in revenue during the third quarter